Seropositive Rheumatoid Arthritis Drug Market Research Report- Forecast to 2027

Seropositive Rheumatoid Arthritis Drug Market Research Report: By Drug Class (Nsaid, Dmards, Biologics), Treatment (Synovectomy, Tendon Repair, Joint Fusion), Diagnosis, Drug, Application, Route Of Administration, End User – Global Forecast Till 2027

ID: MRFR/Pharma/4123-HCR | February 2021 | Region: Global | 90 pages

Please note that the assessment period of report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario:


Arthritis means inflammation in a joint. The inflammation is characterized by swelling, pain, and redness within the joint. This type of arthritis is known to cause chronic inflammatory disorder in the hands and feet.


There are two types of rheumatoid arthritis are seronegative rheumatoid arthritis and seropositive rheumatoid arthritis. Smoking and family history are considered as some of the major cause of rheumatoid arthritis.


The rising R&D of product pipeline along with the introduction of novel products are some of the major trends in this market. For instance, in February 2016, Pfizer received FDA approval for commercialization of XELJANZ XR (tofacitinib citrate) in the U.S. market. The company launched the product in Europe for the treatment of rheumatoid arthritis. In May 2017, Sanofi received FDA approval for Kevzara drug for its commercialization in the U.S. market. Kevzara is used in the treatment of active rheumatoid arthritis.


The global seropositive rheumatoid arthritis drug market is expected to be driven by factors such as rising cigarette consumption, growing healthcare expenditure, increasing female population, and increasing obese population. However, the growth of this industry is hindered by increasing treatment costs and high cost associated with R&D. The global seropositive rheumatoid arthritis drug market is rather concentrated with few pharmaceutical companies dominating the market through new drug approval.


The global seropositive rheumatoid arthritis drug market is expected to grow at a CAGR of approximately 4.0% during the forecast period 2017-2023.


Intended Audience



  • Seropositive Rheumatoid Arthritis Drug Suppliers

  • Seropositive Rheumatoid Arthritis Drug Manufacturers

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


Research Methodology


 seropositive rheumatoid arthritis drug market


Sources: Annual reports, Press release, White paper, and Company presentation


Segmentation                                                                                                


The global seropositive rheumatoid arthritis drug market is segmented on the basis of the drug class, drug, treatment and diagnosis, route of administration, application, and end user.


On the basis of the drug class, the global seropositive rheumatoid arthritis drug market is segmented into Non-steroidal anti-inflammatory drug type (NSAID), Steroids, and Disease-modifying anti-rheumatic drug type (DMARDs) and biologic agents.


On the basis of the drug, the global seropositive rheumatoid arthritis drug market is segmented into Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab), Rituxan (rituximab), Actemra (tocilizumab), Orencia (abatacept), and others.


On the basis of the treatment, the global seropositive rheumatoid arthritis drug market is segmented into synovectomy, tendon repair, joint fusion, and total joint replacement.


On the basis of the diagnosis, the global seropositive rheumatoid arthritis drug market is segmented into C -reactive protein (CRP) Test, CCP, ESR (Erythrocyte Sedimentation Rate) Test and Synovial Fluid Analysis.


On the basis of the route of administration, the global seropositive rheumatoid arthritis drug market is segmented into oral, subcutaneous, intravenous, and others.


On the basis of the application, the global seropositive rheumatoid arthritis drug market is segmented into medicine, scientific research, and others.


On the basis of the end user, the global seropositive rheumatoid arthritis drug market is segmented into hospital, diagnostic centers, ambulatory surgical centers, and others


Regional Analysis


The global seropositive rheumatoid arthritis drug market is segmented into the Americas, Europe, Asia Pacific and the Middle East and Africa.


The Americas dominated the overall market in terms of revenue in 2016 owing to the growing prevalence of arthritis, and rising cases of inflammation in the U.S.


Europe is the second largest rheumatoid market in the globe. The U.K is a major contributor to the European market. As per the National Rheumatoid Arthritis Society (NRAS), it was estimated that approximately 690,000 people suffer from rheumatoid arthritis in the U.K. Moreover, the government bodies are undertaking initiatives for the spreading awareness regarding rheumatoid arthritis is influencing the market growth.


The Asia Pacific is expected to be the fastest growing region, which accounts for more than 60% of the global population. The region has the potential to provide great opportunities for researchers to analyze the pathogenesis, epidemiology, and the factors that influence various manufacturers for expansion and setting up their manufacturing unit in this region.


The Middle East & Africa region contribute the least share of the global seropositive rheumatoid arthritis market owing to the low R&D activities, lack of awareness, and poor medical facilities.


Key Players


Some of key the players in the global seropositive rheumatoid arthritis drug market are Abbott Laboratories (U.S.),  Johnson & Johnson Limited (U.S.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), and Eli Lilly and Company (U.S.), AbbVie Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Amgen (U.S.), Vertex Pharmaceuticals Incorporated (U.S), Sanofi-Aventis (France), AstraZeneca (U.K), Cadila Healthcare Ltd. (India), GlaxoSmithKline Inc. (U.S.), Merck and Co. Inc. (U.S.), and others



TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Treatment Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Seropositive rheumatoid arthritis drug Market, by Drug Class

6.1 Introduction

6.2 Non-steroidal anti-inflammatory drug type (NSAID)

6.2.1 Market Estimates & Forecast, 2020 – 2027

6.3 Steroids

6.3.1 Market Estimates & Forecast, 2020 – 2027

6.4 Disease-modifying anti-rheumatic drug type (DMARDs)

6.4.1 Market Estimates & Forecast, 2020 – 2027

6.5 Biologic agents

6.5.1 Market Estimates & Forecast, 2020 – 2027

Chapter 7. Global Seropositive rheumatoid arthritis drug Market, by Drug

7.1 Introduction

7.2 Humira (adalimumab)

7.2.1 Market Estimates & Forecast, 2020 – 2027

7.3 Enbrel (etanercept)

7.3.1 Market Estimates & Forecast, 2020 – 2027

7.4 Remicade (infliximab)

7.4.1 Market Estimates & Forecast, 2020 – 2027

7.5 Rituxan (rituximab)

7.5.1 Market Estimates & Forecast, 2020 – 2027

7.6 Actemra (tocilizumab)

7.6.1 Market Estimates & Forecast, 2020 – 2027

7.7 Orencia (abatacept)

7.7.1 Market Estimates & Forecast, 2020 – 2027

7.8 Others

Chapter 8. Global Seropositive rheumatoid arthritis drug Market, by Treatment

8.1 Introduction

8.2 Synovectomy

8.2.1 Market Estimates & Forecast, 2020 – 2027

8.3 Tendon repair

8.3.1 Market Estimates & Forecast, 2020 – 2027

8.4 Joint fusion

8.4.1 Market Estimates & Forecast, 2020 – 2027

8.5 Total joint replacement

8.5.1 Market Estimates & Forecast, 2020 – 2027

Chapter 9. Global Seropositive rheumatoid arthritis drug Market, by Diagnosis

9.1 Introduction

9.2 C - reactive protein (CRP) Test

9.2.1 Market Estimates & Forecast, 2020 – 2027

9.3 CCP

9.3.1 Market Estimates & Forecast, 2020 – 2027

9.4 ESR (Erythrocyte Sedimentation Rate) Test

9.4.1 Market Estimates & Forecast, 2020 – 2027

9.5 Synovial Fluid Analysis

9.5.1 Market Estimates & Forecast, 2020 – 2027

Chapter 10. Global Seropositive rheumatoid arthritis drug Market, by Route of administration

10.1 Introduction

10.2 Oral

10.2.1 Market Estimates & Forecast, 2020 – 2027

10.3 Subcutaneous

10.3.1 Market Estimates & Forecast, 2020 – 2027

10.4 Intravenous

10.4.1 Market Estimates & Forecast, 2020 – 2027

10.5 Others

Chapter 11. Global Seropositive rheumatoid arthritis drug Market, by Application

11.1 Introduction

11.2 Medicine

11.2.1 Market Estimates & Forecast, 2020 – 2027

11.3 Scientific research

11.3.1 Market Estimates & Forecast, 2020 – 2027

11.4 Others

Chapter 12. Global Seropositive rheumatoid arthritis drug Market, by End User

12.1 Introduction

12.2 Hospital

12.2.1 Market Estimates & Forecast, 2020 – 2027

12.3 Diagnostic centers

12.3.1 Market Estimates & Forecast, 2020 – 2027

12.4 Ambulatory surgical centers

12.4.1 Market Estimates & Forecast, 2020 – 2027

12.5 Others

Chapter. 11 Global Seropositive rheumatoid arthritis drug Market, by Region

11.1 Introduction

11.2 Americas

11.2.1 North America

11.2.1.1 U.S.

11.2.1.2 Canada

11.2.2 South America

11.3 Europe

11.3.1 Western Europe

11.3.1.1 Germany

11.3.1.2 France

11.3.1.3 Italy

11.3.1.4 Spain

11.3.1.5 U.K

11.3.1.6 Rest of Western Europe

11.3.2 Eastern Europe

11.4 Asia Pacific

11.4.1 Japan

11.4.2 China

11.4.3 India

11.4.4 Australia

11.4.5 Republic of Korea

11.4.6 Rest of Asia Pacific

11.5 The Middle East & Africa

11.5.1 United Arab Emirates

11.5.2 Saudi Arabia

11.5.3 Rest of the Middle East & Africa

Chapter 12 Company Landscape

12.1 Introduction

12.2 Market Share Analysis

12.3 Key Development & Strategies

12.3.1 Key Developments

Chapter 13 Company Profiles

13.1 AbbVie Inc.

13.1.1 Company Overview

13.1.2 Route of administration Overview

13.1.3 Financials

13.1.4 SWOT Analysis

13.2 Abbott Laboratories

13.2.1 Company Overview

13.2.2 Route of administration Overview

13.2.3 Financial Overview

13.2.4 Key Developments

13.2.5 SWOT Analysis

13.3 Johnson & Johnson Limited

13.3.1 Company Overview

13.3.2 Route of administration Overview

13.3.3 Financial Overview

13.3.4 Key Development

13.3.5 SWOT Analysis

13.4 Pfizer, Inc.

13.4.1 Company Overview

13.4.2 Route of administration/Business Segment Overview

13.4.3 Financial Overview

13.4.4 Key Development

13.4.5 SWOT Analysis

13.5 GlaxoSmithKline Inc.

13.5.1 Company Overview

13.5.2 Route of administration Overview

13.5.3 Financial overview

13.5.4 Key Developments

13.6 Novartis AG

13.6.1 Company Overview

13.6.2 Route of administration Overview

13.6.3 Financial Overview

13.6.4 Key Developments

13.7 Sanofi-Aventis

13.7.1 Overview

13.7.2 Route of administration Overview

13.7.3 Financials

13.7.4 Key Developments

13.7.5 SWOT Analysis

13.8 AstraZeneca

13.8.1 Company Overview

13.8.2 Route of administration/Business Segment Overview

13.8.3 Financial Overview

13.8.4 Key Development

13.8.5 SWOT Analysis

13.9 Merck and Co. Inc.

13.9.1 Company Overview

13.9.2 Route of administration Overview

13.9.3 Financial overview

13.9.4 Key Developments

13.10 Others

Chapter 14 MRFR Conclusion

14.1 Key Findings

14.1.1 From CEO’s View Point

14.1.2 Unmet Needs of the Market

14.2 Key Companies to Watch

14.3 Prediction of Pharmaceutical industry

Chapter 15 Appendix

LIST OF TABLES

Table 1 Seropositive rheumatoid arthritis drug Industry Synopsis, 2020 – 2027

Table 2 Seropositive rheumatoid arthritis drug Market Estimates and Forecast, 2020 – 2027, (USD Million)

Table 3 Seropositive rheumatoid arthritis drug Market by Region, 2020 – 2027, (USD Million)

Table 4 Seropositive rheumatoid arthritis drug Market by Drug, 2020 – 2027, (USD Million)

Table 5 Seropositive rheumatoid arthritis drug Market by Drug Class, 2020 – 2027, (USD Million)

Table 6 Seropositive rheumatoid arthritis drug Market by Diagnosis, 2020 – 2027, (USD Million)

Table 7 Seropositive rheumatoid arthritis drug Market by Route of administration, 2020 – 2027, (USD Million)

Table 8 Seropositive rheumatoid arthritis drug Market by Treatment, 2020 – 2027, (USD Million)

Table 9 Seropositive rheumatoid arthritis drug Market by Applications, 2020 – 2027, (USD Million)

Table 10 Seropositive rheumatoid arthritis drug Market by End User, 2020 – 2027, (USD Million)

Table 11 North America Seropositive rheumatoid arthritis drug Market by Drug, 2020 – 2027, (USD Million)

Table 12 North America Seropositive rheumatoid arthritis drug Market by Drug Class, 2020 – 2027, (USD Million)

Table 13 North America Seropositive rheumatoid arthritis drug Market by Diagnosis, 2020 – 2027, (USD Million)

Table 14 North America Seropositive rheumatoid arthritis drug Market by Route of administration, 2020 – 2027, (USD Million)

Table 15 North America Seropositive rheumatoid arthritis drug Market by Treatment, 2020 – 2027, (USD Million)

Table 16 North America Seropositive rheumatoid arthritis drug Market by Application, 2020 – 2027, (USD Million)

Table 17 North America Seropositive rheumatoid arthritis drug Market by End User, 2020 – 2027, (USD Million)

Table 18 US Seropositive rheumatoid arthritis drug Market by Drug, 2020 – 2027, (USD Million)

Table 19 US Seropositive rheumatoid arthritis drug Market by Drug Class, 2020 – 2027, (USD Million)

Table 20 US Seropositive rheumatoid arthritis drug Market by Diagnosis, 2020 – 2027, (USD Million)

Table 21 US Seropositive rheumatoid arthritis drug Market by Route of administration, 2020 – 2027, (USD Million)

Table 22 US Seropositive rheumatoid arthritis drug Market by Treatment, 2020 – 2027, (USD Million)

Table 23 US Seropositive rheumatoid arthritis drug Market by Application, 2020 – 2027, (USD Million)

Table 24 US Seropositive rheumatoid arthritis drug Market by End User, 2020 – 2027, (USD Million)

Table 25 Canada Seropositive rheumatoid arthritis drug Market by Drug, 2020 – 2027, (USD Million)

Table 26 Canada Seropositive rheumatoid arthritis drug Market by Drug Class, 2020 – 2027, (USD Million)

Table 27 Canada Seropositive rheumatoid arthritis drug Market by Diagnosis, 2020 – 2027, (USD Million)

Table 28 Canada Seropositive rheumatoid arthritis drug Market by Route of administration, 2020 – 2027, (USD Million)

Table 29 Canada Seropositive rheumatoid arthritis drug Market by Treatment, 2020 – 2027, (USD Million)

Table 30 Canada Seropositive rheumatoid arthritis drug Market by Application, 2020 – 2027, (USD Million)

Table 31 Canada Seropositive rheumatoid arthritis drug Market by End User, 2020 – 2027, (USD Million)

Table 32 South America Seropositive rheumatoid arthritis drug Market by Drug, 2020 – 2027, (USD Million)

Table 33 South America Seropositive rheumatoid arthritis drug Market by Drug Class, 2020 – 2027, (USD Million)

Table 34 South America Seropositive rheumatoid arthritis drug Market by Diagnosis, 2020 – 2027, (USD Million)

Table 35 South America Seropositive rheumatoid arthritis drug Market by Route of administration, 2020 – 2027, (USD Million)

Table 36 South America Seropositive rheumatoid arthritis drug Market by Treatment, 2020 – 2027, (USD Million)

Table 37 South America Seropositive rheumatoid arthritis drug Market by Application, 2020 – 2027, (USD Million)

Table 38 South America Seropositive rheumatoid arthritis drug Market by End User, 2020 – 2027, (USD Million)

Table 39 Europe Seropositive rheumatoid arthritis drug Market by Drug, 2020 – 2027, (USD Million)

Table 40 Europe Seropositive rheumatoid arthritis drug Market by Drug Class, 2020 – 2027, (USD Million)

Table 41 Europe Seropositive rheumatoid arthritis drug Market by Diagnosis, 2020 – 2027, (USD Million)

Table 42 Europe Seropositive rheumatoid arthritis drug Market by Route of administration, 2020 – 2027, (USD Million)

Table 43 Europe Seropositive rheumatoid arthritis drug Market by Treatment, 2020 – 2027, (USD Million)

Table 44 Europe Seropositive rheumatoid arthritis drug Market by Application, 2020 – 2027, (USD Million)

Table 45 Europe Seropositive rheumatoid arthritis drug Market by End User, 2020 – 2027, (USD Million)

Table 46 Western Europe Seropositive rheumatoid arthritis drug Market by Drug, 2020 – 2027, (USD Million)

Table 47 Western Europe Seropositive rheumatoid arthritis drug Market by Drug Class, 2020 – 2027, (USD Million)

Table 48 Western Europe Seropositive rheumatoid arthritis drug Market by Diagnosis, 2020 – 2027, (USD Million)

Table 49 Western Europe Seropositive rheumatoid arthritis drug Market by Route of administration, 2020 – 2027, (USD Million)

Table 50 Western Europe Seropositive rheumatoid arthritis drug Market by Treatment, 2020 – 2027, (USD Million)

Table 51 Western Europe Seropositive rheumatoid arthritis drug Market by Application, 2020 – 2027, (USD Million)

Table 52 Western Europe Seropositive rheumatoid arthritis drug Market by End User, 2020 – 2027, (USD Million)

Table 53 Eastern Europe Seropositive rheumatoid arthritis drug Market by Drug, 2020 – 2027, (USD Million)

Table 54 Eastern Europe Seropositive rheumatoid arthritis drug Market by Drug Class, 2020 – 2027, (USD Million)

Table 55 Eastern Europe Seropositive rheumatoid arthritis drug Market by Diagnosis, 2020 – 2027, (USD Million)

Table 56 Eastern Europe Seropositive rheumatoid arthritis drug Market by Route of administration, 2020 – 2027, (USD Million)

Table 57 Eastern Europe Seropositive rheumatoid arthritis drug Market by Treatment, 2020 – 2027, (USD Million)

Table 58 Eastern Europe Seropositive rheumatoid arthritis drug Market by Application, 2020 – 2027, (USD Million)

Table 59 Eastern Europe Seropositive rheumatoid arthritis drug Market by End User, 2020 – 2027, (USD Million)

Table 60 Asia Pacific Seropositive rheumatoid arthritis drug Market by Drug, 2020 – 2027, (USD Million)

Table 61 Asia Pacific Seropositive rheumatoid arthritis drug Market by Drug Class, 2020 – 2027, (USD Million)

Table 62 Asia Pacific Seropositive rheumatoid arthritis drug Market by Diagnosis, 2020 – 2027, (USD Million)

Table 63 Asia Pacific Seropositive rheumatoid arthritis drug Market by Route of administration, 2020 – 2027, (USD Million)

Table 64 Asia Pacific Seropositive rheumatoid arthritis drug Market by Treatment, 2020 – 2027, (USD Million)

Table 65 Asia Pacific Seropositive rheumatoid arthritis drug Market by Application, 2020 – 2027, (USD Million)

Table 66 Asia Pacific Seropositive rheumatoid arthritis drug Market by End User, 2020 – 2027, (USD Million)

Table 67 The Middle East & Africa Seropositive rheumatoid arthritis drug Market by Drug, 2020 – 2027, (USD Million)

Table 68 The Middle East & Africa Seropositive rheumatoid arthritis drug Market by Drug Class, 2020 – 2027, (USD Million)

Table 69 The Middle East & Africa Seropositive rheumatoid arthritis drug Market by Diagnosis, 2020 – 2027, (USD Million)

Table 70 The Middle East & Africa Seropositive rheumatoid arthritis drug Market by Route of administration, 2020 – 2027, (USD Million)

Table 71 The Middle East & Africa Seropositive rheumatoid arthritis drug Market by Treatment, 2020 – 2027, (USD Million)

Table 72 The Middle East & Africa Seropositive rheumatoid arthritis drug Market by Application, 2020 – 2027, (USD Million)

Table 73 The Middle East & Africa Seropositive rheumatoid arthritis drug Market by End User, 2020 – 2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Seropositive rheumatoid arthritis drug Market

Figure 3 Segmentation Market Dynamics for Seropositive rheumatoid arthritis drug Market

Figure 4 Global Seropositive rheumatoid arthritis drug Market Share, by Drug 2020

Figure 5 Global Seropositive rheumatoid arthritis drug Market Share, by Drug Class 2020

Figure 6 Global Seropositive rheumatoid arthritis drug Market Share, by Diagnosis 2020

Figure 7 Global Seropositive rheumatoid arthritis drug Market Share, by Route of administration, 2020

Figure 8 Global Seropositive rheumatoid arthritis drug Market Share, by Treatment, 2020

Figure 9 Global Seropositive rheumatoid arthritis drug Market Share, by Applications, 2020

Figure 10 Global Seropositive rheumatoid arthritis drug Market Share, by End User, 2020

Figure 11 Global Seropositive rheumatoid arthritis drug Market Share, by Region, 2020

Figure 12 North America Seropositive rheumatoid arthritis drug Market Share, by Country, 2020

Figure 13 Europe Seropositive rheumatoid arthritis drug Market Share, by Country, 2020

Figure 14 Asia Pacific Seropositive rheumatoid arthritis drug Market Share, by Country, 2020

Figure 15 The Middle East & Africa Seropositive rheumatoid arthritis drug Market Share, by Country, 2020

Figure 16 Global Seropositive rheumatoid arthritis drug Market: Company Share Analysis, 2020 (%)

Figure 17 AbbVie Inc.: Key Financials

Figure 18 AbbVie Inc.: Segmental Revenue

Figure 19 AbbVie Inc.: Geographical Revenue

Figure 20 Abbott Laboratories: Key Financials

Figure 21 Abbott Laboratories: Segmental Revenue

Figure 22 Abbott Laboratories: Geographical Revenue

Figure 23 Johnson & Johnson Limited: Key Financials

Figure 24 Johnson & Johnson Limited: Segmental Revenue

Figure 25 Johnson & Johnson Limited: Geographical Revenue

Figure 26 Pfizer, Inc.: Key Financials

Figure 27 Pfizer, Inc.: Segmental Revenue

Figure 28 Pfizer, Inc.: Geographical Revenue

Figure 29 GlaxoSmithKline Inc.: Key Financials

Figure 30 GlaxoSmithKline Inc.: Segmental Revenue

Figure 31 GlaxoSmithKline Inc.: Geographical Revenue

Figure 32 Novartis AG: Key Financials

Figure 33 Novartis AG: Segmental Revenue

Figure 34 Novartis AG: Geographical Revenue

Figure 35 Sanofi-Aventis: Key Financials

Figure 36 Sanofi-Aventis: Segmental Revenue

Figure 37 Sanofi-Aventis: Geographical Revenue

Figure 38 AstraZeneca: Key Financials

Figure 39 AstraZeneca: Segmental Revenue

Figure 40 AstraZeneca: Geographical Revenue

Figure 41 Merck and Co. Inc.: Key Financials

Figure 42 Merck and Co. Inc.: Segmental Revenue

Figure 43 Merck and Co. Inc.: Geographical Revenue